R&D | May 23, 2026
WACKER launches contract research services to accelerate next-gen RNA & DNA therapies
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Subscribe To Our Newsletter & Stay Updated
